Article Details

GSK co-leads investment in 'disease rebalancing' Adrestia Therapeutics

Retrieved on: 2020-12-18 09:45:00

Tags for this article:

Click the tags to see associated articles and topics

GSK co-leads investment in 'disease rebalancing' Adrestia Therapeutics. View article details on hiswai:

Excerpt

Adrestia uses <b>molecular biology</b> to develop precision medicines – its 'disease rebalancing' platform uses <b>molecular biology</b> to restore the biological ...

Article found on: www.pharmatimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up